semaglutide life extension as a GLP-1 Agonist: A Breakthrough in Obesity Treatment How Long Can You Take

What I want patients and clinicians to take away from this is that if you or your patient has obesity, established cardiovascular disease, type 2 diabetes, CKD, HFpEF, MASH, or sleep apnea, this drug class should be a serious part of the treatment conversation

D., Koumanov, F., & Gonzalez, J

The picture only became reliable once researchers applied antibodies validated against knockout tissue, RNA in situ hybridization, and transgenic reporter models

Results Patient demographics To study perioperative GLP-1 and GLP-2 plasma concentration dynamics, we included 46 patients, undergoing minor (n = 26) or major (n = 20) hepatic resections